IGF-1
Increase · large
Ghrelin receptor agonist
Literature evidence
Compound library
Vivy evidence dossier
MK-677 (Ibutamoren)
Also indexed as Ibutamoren, L-163,191, MK-677
T2Peptides
Read this entry as context, not instruction.
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
Pharmacokinetic context
Half-life6 hr
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Biomarker context
Fasting glucose
Increase · small
Transient insulin resistance
Literature evidence
Growth hormone
Increase · large
Stimulates pituitary GH release
Literature evidence
IGFBP-3
Increase · moderate
GH-mediated binding proteins
Literature evidence
Cortisol (AM)
Decrease · small
Improves sleep architecture
Literature evidence
Sleep efficiency
Increase · moderate
Improves sleep quality
Literature evidence
Melatonin (endogenous)
Modulate · small
Circadian regulation
Literature evidence
Appetite
Increase · moderate
Ghrelin agonism
Literature evidence
Water retention
Increase · small
GH-related fluid retention
Literature evidence
HbA1c
Increase · small
May worsen glycemic control
Literature evidence
Fasting insulin
Increase · small
Insulin resistance
Literature evidence
Edema
Increase · small
GH-related fluid retention
Literature evidence
Ghrelin
Increase · large
Ghrelin receptor agonism
Literature evidence
Keep in view
Safety discussion points
MK-677 is an oral ghrelin mimetic (GHS) that stimulates GH and IGF-1 secretion. Not FDA-approved. Available as oral tablet.
Keep the reference close
Track MK-677 (Ibutamoren) in context.
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.